Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 26.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

Evolent Health’s second quarter results drew a significant positive market reaction, reflecting outperformance versus Wall Street’s expectations on both revenue and profitability. Management pointed to the successful launch of the Highmark contract and robust customer renewals as key drivers. CEO Seth Blackley specifically highlighted that clinical engagement metrics for new partnerships, such as Aetna and Highmark, were trending above target, signaling strong execution in the company’s core val

Highmark launch drove 47% revenue growth; AI platform reached meaningful scale.

Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.

Boeing upgraded, Under Armour downgraded: Wall Street's top analyst calls

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on year to $652.5 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $0.02 per share was significantly above analysts’ consensus estimates.

Evolent Health (NYSE:EVH) reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business. Chief E

Moby summary of Evolent Health, Inc.'s Q2 2026 earnings call

Evolent Health Inc (EVH) delivers robust Q2 2026 results with record revenue and EBITDA, while navigating Medicaid headwinds and setting sights on 25%+ growth in 2027.

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) delivered earnings and revenue surprises of +300.00% and +6.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on year to $652.5 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $0.02 per share was significantly above analysts’ consensus estimates.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Tempus (TEM) delivered earnings and revenue surprises of +69.23% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PHG lifts its 2026 profit and free cash flow outlook after Q2 earnings increase on higher sales, productivity gains and a U.S. tariff refund benefit.

Shares of healthcare solutions company Evolent Health (NYSE:EVH) fell 13% in the afternoon session after Wall Street firm Citi downgraded the company's stock from Buy to Neutral. Despite raising the price target from $5.50 to $6.75, the investment firm reassessed the stock's potential, citing a less attractive risk-to-reward setup following a recent price increase. Analysts highlighted uncertainties surrounding healthcare exchange dis-enrollment and shifts in patient care needs. Additionally, Ci

The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

American Well (AMWL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.